Overview

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Actelion
Treatments:
Macitentan